Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

CCB International

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 61
Average round size
info
The average size of a deal this fund participated in
$281M
Portfolio companies 57
Rounds per year 1.61
Lead investments 14
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.07
Exits 6
Key employees 2
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Artificial Intelligence
Summary

The leading representative office of defined VC is situated in the Hong Kong. The venture was found in Asia in Hong Kong.

We also calculated 2 valuable employees in our database.

Deals in the range of more than 100 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. This CCB International works on 19 percentage points less the average amount of lead investments comparing to the other organizations. The typical startup value when the investment from CCB International is more than 1 billion dollars. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually. Considering the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations.

The fund has no exact preference in some founders of portfolio startups. If startup sums 3 or 4 of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Pharmaceutical, Automotive. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Ant Financial, Toutiao, Shouqi Car Rental For fund there is no match between the location of its establishment and the land of its numerous investments - China.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the CCB International, startups are often financed by Qiming Venture Partners, Sequoia Capital China, IP Group Plc. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, Qiming Venture Partners, YF Capital (Yunfeng Capital). In the next rounds fund is usually obtained by San Shan Capital, General Atlantic, CITIC Capital Holdings.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CCB International:
Typical Co-investors
CCB International is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CCB International:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

GalaxySpace

Satellite Communication
07 Sep 2022 Dongcheng District, Beijing, China

Origin Quantum

Cloud Computing
Hardware
Information Technology
$154M22 Jul 2022 Hefei, Anhui, China

SJ Semi

Industrial
Manufacturing
Semiconductor
$300M18 Mar 2022 Jiangyin City, Jiangsu, China

MiRXES Pte Ltd

Biotechnology
Health Care
Life Science
$87M22 Feb 2022 Singapore, Central, Singapore

Tianbing Technology

Aerospace
Travel
$15M08 Feb 2022 Dongcheng District, Beijing, China

Moore Threads

Artificial Intelligence
Gaming
Hardware
Semiconductor
$309M25 Nov 2021 Haidian District, Beijing, China

Wego

Medical Device
$155M29 Oct 2021 Nanshan, Hunan, China

Hozon

Automotive
Electric Vehicle
Manufacturing
$618M27 Oct 2021 Shanghai, China

IASO Biotherapeutics

Biotechnology
Pharmaceutical
$108M16 Sep 2021 Xuanwu District, Jiangsu, China
News
IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies

– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CCB International?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: